NEWS

The Epic Sciences™ platform technology is designed to find CTC’s from a tube of blood with millions of cells, is adaptable to multiple sample sources and can be customized to target a variety of different biomarkers. If you are trying to find one, we may be able to help you.

DDNEWS: Non-invasive of the body snachers

PharmaVOICE has named Dena Marinucci, Ph.D. CSO of Epic Sciences, to the magazine's 2015 list of 100 outstanding professionals in the life-sciences industry. Dena was chosen as part of the group of visionary entrepreneurs who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.

GenomeWeb reported from the annual meeting of the American Association for Cancer Research (AACR), where several research groups presented studies using Epic Science's no cell left behind™ platform for detecting and analyzing circulating tumor cells (CTCs). One of the studies featured in the article was one of our own, in which we used the Epic platform and next generation sequencing technology to isolate CTCs from experimental samples and perform single cell genomic analysis.

Epic Sciences has received its Clinical Laboratory Improvement Amendments (CLIA) license from the Centers for Medicare and Medicaid Services and the State of California for its circulating tumor cell lab in San Diego to advance new cancer diagnostics.

Epic's no cell left behind™ technology allows for a full assessment of non-small cell lung cancer (NSCLC) biomarkers from a single tube of blood, inclusive of EGFR, KRAS, ALK, MET, RET, and ROS1.

Epic Sciences' circulating tumor cell (CTC) no cell left behind™ technology was featured in Cancer Discovery's May 2014 issue. The article discusses how quantifying and characterizing circulating tumor cells (CTC), as a liquid biopsy, is helping doctors to determine the course of therapy and to watch how a patient’s cancer evolves—all with a blood draw.

Epic's circulating tumor cell (CTC) technology was featured in the April 2014 issue of The Scientist. The article discusses how our no cell left behind™ technology can capture all of the CTCs in a blood sample, because Epic's approach does not rely on cell-enrichment strategies. Our imaging system captures pictures of all the cells on the slide (approximately 3 million), records the precise coordinates of each cell, and analyzes each cell for 90 different parameters—the fluorescence intensity of the four fluorescent markers and 86 different morphological parameters.

Blood samples are an invaluable tool, but often they’re just the tip of the diagnostic iceberg, something that determines whether additional, more sensitive tests and scans might be necessary. But new technology may make it possible to use individual cells in a patient’s blood sample to get far more specific and actionable information. A technique being developed by San Diego–based Epic Sciences can determine whether a cancer patient is an appropriate candidate for a drug, and even whether the drug is losing its efficacy.

San Diego’s Epic Sciences said today it has signed an agreement with LabCorp (NYSE: LH) to help speed up European clinical trials that are using Epic’s technology to identify tumor cells in the blood.